Bitopertin’s Schizophrenia Failure Stirs Doubt About Roche’s CNS Plans
This article was originally published in The Pink Sheet Daily
Roche’s bitopertin fails in the first two of six Phase III schizophrenia trials to report, raising questions about prospects for more diversity outside the company’s core strength in oncology.
You may also be interested in...
Roche plans to file I.V. anti-CD20 antibody ocrelizumab in multiple sclerosis early in 2016, after disclosing that the drug met endpoints in two Phase III studies against Merck Serono’s Rebif.
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.